BRII-297
/ Brii Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
January 18, 2024
A Study of BRII-297 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=41 | Completed | Sponsor: Brii Biosciences Limited | Recruiting ➔ Completed
Trial completion • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
August 18, 2023
A Study of BRII-297 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=52 | Recruiting | Sponsor: Brii Biosciences Limited | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
May 31, 2023
Brii Biosciences Announces First Subject Dosed in Phase 1 Clinical Trial of BRII-297, Long-Acting Injectable for the Treatment of Anxiety and Depressive Disorders
(PRNewswire)
- "Brii Biosciences Limited...announced the first subject has been dosed in a Phase 1 clinical trial evaluating BRII-297, a first-of-its-kind long-acting injectable (LAI), in development for the treatment of various anxiety and depressive disorders. This Phase 1 study is examining the safety, tolerability and pharmacokinetics of BRII-297 in healthy volunteers in Australia."
Trial status • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry • Women's Health
May 06, 2023
A Study of BRII-297 in Healthy Adult Subjects
(clinicaltrials.gov)
- P1 | N=52 | Not yet recruiting | Sponsor: Brii Biosciences Limited
New P1 trial • CNS Disorders • Depression • Mood Disorders • Postpartum Depression • Psychiatry
1 to 4
Of
4
Go to page
1